Answers are grounded in this paper and cite their sources.
Esophageal adenocarcinoma (EAC) is molecularly heterogeneous, and prognostic models with clear biological context remain limited. We analyzed RNA-sequencing and clinical data from 46 EAC tumors and 13 adjacent normal tissues in The Cancer Genome Atlas. Differential expression, ESTIMATE, weighted gene co-expression network analysis, and LASSO–Cox regression were used to derive a tumor microenvironment-associated score, followed by bootstrap and nested cross-validation, assessment in independent cohorts, immune deconvolution, and single-nucleus RNA-sequencing analysis. We identified 1571 differentially expressed genes and an 879-gene module associated with stromal, immune, and tumor-purity traits. A four-gene score comprising ACSM1, AGT, IGF2BP3, and ESM1 stratified overall survival in the development cohort. The optimism-corrected C-index was 0.769, whereas the median nested cross-validation C-index was 0.589. In GSE13898, the locked score identified Cluster B with a rank AUC of 0.923; however, survival associations were not reproduced in GSE72873 or GSE254942. Immune-cell comparisons showed nominal differences that did not remain significant after BH correction. Single-nucleus analysis localized IGF2BP3 mainly to malignant cells and ESM1 to endothelial cells. The score provides molecular-subtype and cellular context for hypothesis generation, but its prognostic generalizability remains unestablished.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: